Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY: ADCT )

1.960 -0.160 (-7.55%)
Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 Next >
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why
Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a promising oncology pipeline. Overweight rating, $6 price target. 
Via Benzinga
ADC Therapeutics's Earnings: A Preview
Via Benzinga
ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q2 2024
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
7 Growth Stocks to Buy for Under $5 for Massive Gains
Although growth stocks under $5 are inherently risky and unpredictable, their very nature also facilitates robust upside potential. 
Via InvestorPlace
Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. 
Via InvestorPlace
A Preview Of ADC Therapeutics's Earnings
Via Benzinga
ADC Therapeutics - Time For A Turn-Around?
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. 
Via Talk Markets
Analyst Expectations for ADC Therapeutics's Future
Via Benzinga
ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Medifast Reports Mixed Results, Joins Coursera, Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday
U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
The Latest Analyst Ratings for ADC Therapeutics
Via Benzinga
A Preview Of ADC Therapeutics's Earnings
Via Benzinga
4 Analysts Have This to Say About ADC Therapeutics
Via Benzinga
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
Alaska Air To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider. 
Via InvestorPlace
Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 54 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths
ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with... 
Via Benzinga
Dow Rises More Than 200 Points; Adial Pharmaceuticals Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 200 points on Tuesday. The Dow traded up 0.73% to 34,193.60 while the NASDAQ rose 0.25% to 13,720.16. The S&P... 
Via Benzinga
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday. 
Via Benzinga
Crude Oil Rises 2%; ADC Therapeutics Shares Plummet
U.S. stocks traded higher midway through trading, with the Dow Jones surging over 100 points on Tuesday. The Dow traded up 0.41% to 34,082.47 while the NASDAQ rose 0.29% to 13,725.52. The S&P 500, also... 
Via Benzinga
Dow Jumps Over 100 Points; US Small Business Optimism Index Tops Estimates
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.40% to 34,080.13 while the NASDAQ rose 0.23% to... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Diversified Communications
© 2024 Diversified Communications. All rights reserved.